Liver X receptor-activating ligands modulate renal and intestinal sodium-phosphate transporters

Kidney International

Volumn 80, Issue 5, 2011, Pages 535-544

  Caldas, Yupanqui A ^a,b   Giral, Hector ^a   Cortázar, Michael A ^a,c   Sutherland, Eileen ^a   Okamura, Kayo ^a   Blaine, Judith ^a   Sorribas, Victor ^b   Koepsell, Hermann ^d   Levi, Moshe ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c UNIVERSIDAD DEL VALLE   (Colombia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Arteriosclerosis; Chronic kidney disease; Hyperphosphatemia; Phosphate uptake; Vascular calcification

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; N,N DIMETHYL 3BETA HYDROXYCHOLENAMIDE; PHOSPHATE; SODIUM ION; SODIUM PHOSPHATE COTRANSPORTER; SODIUM PHOSPHATE COTRANSPORTER 4; UNCLASSIFIED DRUG; LIGAND; ORPHAN NUCLEAR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; GENE CONTROL; HYPERPHOSPHATEMIA; INTESTINE BRUSH BORDER MEMBRANE; KIDNEY CELL; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NONHUMAN; OPOSSUM; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; DRUG POTENTIATION; HOMEOSTASIS; HUMAN; INTESTINE; KIDNEY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; URINE;

ANIMALS; BIOLOGICAL TRANSPORT; HOMEOSTASIS; HUMANS; INTESTINES; KIDNEY; LIGANDS; MICE; ORPHAN NUCLEAR RECEPTORS; PHOSPHATES; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS;

EID: 84857073603     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.159     Document Type: Article

References (44)

1. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312-1324.
2. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol 2009; 4: 1136-1139.
3. Foley RN, Collins AJ, Herzog CA et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
4. Ix JH, De Boer IH, Peralta CA et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615.
5. Chiu YW, Adler SG, Budoff MJ et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010; 77: 1107-1114.
6. Villa-Bellosta R, Bogaert YE, Levi M et al. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 2007; 27: 1030-1036. (Pubitemid 46641988)
7. Brandenburg VM, Jahnen-Dechent W, Ketteler M. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation. Kidney Int Suppl 2009; 114: S26-S33.
8. Miyazaki-Anzai S, Levi M, Kratzer A et al. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/-mice with chronic kidney disease. Circ Res 2010; 106: 1807-1817.
9. Virkki LV, Biber J, Murer H et al. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol 2007; 293: F643-F654. (Pubitemid 47403335)
10. Forster IC, Hernando N, Biber J et al. Proximal tubular handling of phosphate: a molecular perspective. Kidney Int 2006; 70: 1548-1559. (Pubitemid 44606989)
11. Kiela PR, Ghishan FK. Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 2009; 89: 7-14.
12. Villa-Bellosta R, Sorribas V. Compensatory regulation of the sodium/phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2) during Pi deprivation and acidosis. Pflugers Arch 2010; 459: 499-508.
13. Breusegem SY, Takahashi H, Giral-Arnal H et al. Differential regulation of the renal sodium-phosphate cotransporters NaPi-IIa, NaPi-IIc, and PiT-2 in dietary potassium deficiency. Am J Physiol Renal Physiol 2009; 297: F350-F361.
14. Giral H, Caldas Y, Sutherland E et al. Regulation of the Rat Intestinal Na-dependent Phosphate Transporters by Dietary Phosphate. Am J Physiol Renal Physiol 2009; 297: F1466-F1475.
15. Sabbagh Y, O'Brien SP, Song W et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20: 2348-2358.
16. Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr Opin Investig Drugs 2008; 9: 247-255. (Pubitemid 351323377)
17. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454: 470-477.
18. Bensinger SJ, Bradley MN, Joseph SB et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008; 134: 97-111. (Pubitemid 351905740)
19. Joseph SB, McKilligin E, Pei L et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-7609. (Pubitemid 34568738)
20. Terasaka N, Hiroshima A, Koieyama T et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003; 536: 6-11. (Pubitemid 36206397)
21. Kim GH, Park K, Yeom SY et al. Characterization of ASC-2 as an antiatherogenic transcriptional coactivator of liver X receptors in macrophages. Mol Endocrinol 2009; 23: 966-974.
22. Kratzer A, Buchebner M, Pfeifer T et al. Synthetic LXR agonist attenuates plaque formation in apoE-/-mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res 2009; 50: 312-326.
23. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008; 18: 461-467. (Pubitemid 50280209)
24. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-993. (Pubitemid 36683707)
25. Wang XX, Jiang T, Levi M. Nuclear hormone receptors in diabetic nephropathy. Nat Rev Nephrol 2010; 6: 342-351.
26. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 2006; 6: 421-427.
27. Peet DJ, Turley SD, Ma W et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998; 93: 693-704. (Pubitemid 28257577)
28. Janowski BA, Willy PJ, Devi TR et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-731. (Pubitemid 26360651)
29. Knight BL, Patel DD, Humphreys SM et al. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 2003; 44: 2049-2058. (Pubitemid 37509620)
30. Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K et al. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 2007; 61: 736-759.
31. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006; 68: 159-191.
32. Quinet EM, Savio DA, Halpern AR et al. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J Lipid Res 2004; 45: 1929-1942. (Pubitemid 40990886)
33. Morello F, de Boer RA, Steffensen KR et al. Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 2005; 115: 1913-1922. (Pubitemid 40979731)
34. Zhang Y, Mangelsdorf DJ. LuXuRies of lipid homeostasis: the unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing. Mol Interv 2002; 2: 78-87.
35. Levy E, Spahis S, Sinnett D et al. Intestinal cholesterol transport proteins: an update and beyond. Curr Opin Lipidol 2007; 18: 310-318. (Pubitemid 46743056)
36. Kaneko E, Matsuda M, Yamada Y et al. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem 2003; 278: 36091-36098. (Pubitemid 37139930)
37. Zhang Y, Zhang X, Chen L et al. Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule. Am J Physiol Renal Physiol 2006; 290: F1065-F1073. (Pubitemid 43724905)
38. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010; 77: 292-298.
39. Hernando N, Deliot N, Gisler SM et al. PDZ-domain interactions and apical expression of type IIa Na/P(i) cotransporters. Proc Natl Acad Sci USA 2002; 99: 11957-11962. (Pubitemid 34994506)
40. Lanaspa MA, Giral H, Breusegem SY et al. Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi. Am J Physiol Renal Physiol 2007; 292: F230-F242. (Pubitemid 46105263)
41. Villa-Bellosta R, Barac-Nieto M, Breusegem SY et al. Interactions of the growth-related, type IIc renal sodium/phosphate cotransporter with PDZ proteins. Kidney Int 2008; 73: 456-464. (Pubitemid 351186289)
42. Sorribas V, Markovich D, Hayes G et al. Cloning of a Na/Pi cotransporter from opossum kidney cells. J Biol Chem 1994; 269: 6615-6621.
43. Sorribas V, Lotscher M, Loffing J et al. Cellular mechanisms of the age-related decrease in renal phosphate reabsorption. Kidney Int 1996; 50: 855-863. (Pubitemid 26302674)
44. Breusegem SY, Halaihel N, Inoue M et al. Acute and chronic changes in cholesterol modulate Na-Pi cotransport activity in OK cells. Am J Physiol Renal Physiol 2005; 289: F154-F165. (Pubitemid 40863583)